Tecentriq Triple Combo Under FDA Review for NSCLC Treatment

NSCLC

Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes.   Tecentriq is a checkpoint inhibitor drug that targets […]

Continue reading

Scientists Discover New Way to Predict Immunotherapy Responses

immunotherapy

Immune checkpoint inhibitors like Keytruda offer new ways to treat cancer patients who might otherwise have no options. But the treatment has posed challenges to health care professionals when it comes to figuring out which tumors will respond to immunotherapy and which tumors won’t. A research team at Memorial Sloan Kettering Cancer Center in New […]

Continue reading

New Video Series Celebrates 22 Late-Stage Cancer Survivors

Last September, 22 people made history as they joined together to celebrate accomplishing the impossible: surviving late-stage cancer. Traveling back to the place where their healing journeys began — CHIPSA Hospital in Tijuana, Mexico — the cancer survivors had the chance to share their stories, meet other patients, and converse with world-renowned doctors, scientists, coaches, and […]

Continue reading

Immunotherapy in 2019: What’s Next for this Cancer Treatment?

immunotherapy

2018 saw tremendous improvements in immunotherapy methods that led to positive results for cancer patients all around the United States. 2019 promises even more advancements, and new strategies aim to increase these effective responses. The key to garnering even better immunotherapy results in 2019 will be using combination therapies. Two methods in particular will be front […]

Continue reading

Immunotherapy Efficacy in Patients with Metastatic Bladder Cancer

immunotherapy and bladder cancer

In the past several years, many checkpoint inhibitors have been approved by the FDA for use in treating patients with metastatic bladder cancer. These drugs offer new options for doctors who are treating these patients, but they also pose the challenge of determining the best order in which to use them. Joaquim Bellmunt, MD, Ph.D., […]

Continue reading

New Immunotherapy Guidelines Will Help Clinicians Treat Lung Cancer

immunotherapy

After the FDA approved Opdivo to treat non-small cell lung cancer (NSCLC) in March of 2015, it replaced cytotoxic chemotherapy as the main method of treatment for the disease. Immunotherapy has since become preferable to chemotherapy, as many new checkpoint inhibitors have also been FDA-approved. But because many immunotherapy treatments were introduced to the lab […]

Continue reading

CHIPSA Hospital: An Oasis of Healing

When you start your journey to heal cancer, you need more than just medicine, specialized foods, and treatment plans. You need love, support, and kindness. You need hope, passion, and joy. You need people on your team who are rooting for you and your life. At CHIPSA Hospital, you get all of that and more. Our […]

Continue reading

On the Brink of Curing Cancer: How Nobel Prize Winners Offer Hope

  The way we understand cancer treatment in the U.S. is changing. This year’s Nobel prizes in medicine honored new scientific breakthroughs that suggest we may be close to finding a cure for cancer. One of the Nobel-prize winners, Dr. James P. Allison, has made great strides in advancing cancer immunotherapy. Immunotherapy is a treatment […]

Continue reading

Two Cutting-Edge Cancer Drugs Now Approved by FDA

New Cancer Drugs

Two new cutting-edge cancer treatments, Vitravki and Xospata, have now been approved for use by the U.S. Food and Drug Administration (FDA). Both drugs were given Priority Review status, which means the FDA reviewed them in six months instead of ten.  This status allows the FDA to quickly approve drugs that promise to make significant […]

Continue reading